EUCTR2007-000886-40-CZ进行中（未招募）1 期
Assessment of the early efficacy response rate of leflunomide according to the initial dosing regimen in the treatment of naïve-DMARD early RA-patients. - LEADER
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female* patients, aged over 18 years .
- •*The inclusion of women of childbearing must strictly respect the following recommendations:
- •- To demonstrate they are not pregnant at the time of study entry, they agree to undergo urine pregnancy testing at inclusion visit. They also agree to undergo urine pregnancy testing at safety follow-up visit.
- •- They are demonstrated not to be breast feeding at the time of study entry.
- •- They agree to maintain adequate means of contraception throughout the study and for 24 months after the discontinuation of treatment or they undergo a washout procedure.
- •- They agree not to get pregnant for 24 months after discontinuation of treatment with study medication or they undergo a washout procedure. In either case (waiting period of 24 months or washout procedure), the A77 1726 plasma concentration has then to be determined two times at an interval of at least 14 days after treatment discontinuation.
- •Male patients must consent to practice contraception during the study and as long as they are taking leflunomide and to follow the washout procedure if they wish to father a child after treatment discontinuation (according to the SmPC).
- •2. Diagnosis of active rheumatoid arthritis in the previous 6 months according to ACR guidelines (in Appendix A).
- •3. Active disease demonstrated by: clinical (tender and swollen joint count, morning stiffness and pain) and biological (CRP > 2.0mg/dl or ESR>28mm/Hg) criteria, to be initiated by DMARD.
- •4. Unchanged doses, for at least 4 weeks before entering the study, of:
- •- oral corticosteroids (with a maximum dose of 10 mg prednisolone daily, or the corticosteroid equivalent administered orally).
- •5. Subjects must be well-orientated, cooperative and willing to comply with the terms of this protocol.
- •6. Informed consent must be obtained for all subjects before enrollment in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patient presenting or having a history of other inflammatory joint disease, e.g. mixed connective tissue disease, seronegative spondylarthropathy, arthropathic psoriasis, Reiter’s syndrome, systemic lupus erythematosus, sarcoidosis, history of Felty’s syndrome, or any arthritis with onset prior to 16 years of age.
- •2. Patients with ongoing or previous Stevens- Johnson syndrome, toxic epidermal necrolysis or erythema multiforme.
- •3. Patients with significantly impaired bone marrow function or significant anaemia, leucopenia or thrombocytopenia due to causes other than active rheumatoid arthritis.
- •4. Persistent infection or severe infection within 3 months before enrollment.
- •5. Uncontrolled hypertension, uncontrolled diabetes, unstable ischemic heart disease, active inflammatory bowel disease, active peptic ulcer disease, terminal illness or other medical condition which, in the opinion of the investigator, would put the patient at risk to participate in the study.
- •6. Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult.
- •7. Severe hypoproteinemia (e.g. in case of severe liver disease or nephrotic syndrome) with serum albumin < 3.0 g/dl.
- •8. Moderate or severe impairment of renal function, as shown by serum creatinine > 133 µmol/L (or 1.5 mg/dL).
- •9. Patients with a history of recent and clinically significant drug or alcohol abuse.
- •10. Impairment of liver function or persisting ALT (SGPT) elevations of more than 2-fold the upper limit of normal.
- •11. Pregnancy.
- •12. Breastfeeding.
- •13. Women of childbearing potential, except if they fulfill all conditions described in
- •section 8.2.
- •14. Men wishing to father children during the course of the study or within the 24 months thereafter (or 3 months with the washout procedure).
- •15. Patient with a congenital or acquired severe immunodeficiency, a history of cancer or lymphoproliferative disease, or any patient who has received total lymphoid irradiation.
- •16. Known HIV positive status.
- •17. Known positive serology for hepatitis B or C.
- •18. Patients with hypersensitivity to any of the excipients in the tablets of leflunomide.
- •19. Previous therapy at any time with:
- •any DMARD including leflunomide, methotrexate , oral or injectable gold salts, chloroquine, hydroxychloroquine, ciclosporin, azathioprine, methotrexate, sulfasalazine)
- •D penicillamine
- •alkylating agents, e.g. cyclophosphamide, chlorambucil, biological agents, e.g. interferon, monoclonal antibodies, growth factor, cytokines
- •any investigational drug
- •any anti metabolites
- •any opiate
- •20. Therapy within the previous 4 weeks with :
- •oral corticosteroids exceeding a prednisolone equivalent of 10 mg/day
- •parenteral or intra-articular corticoid injection
- •21. Any known condition or circumstance which would in the investigator’s opinion prevent compliance or completion of the study
- •Any concomitant disorder (such as diabetes mellitus, hypertension, heart disease, etc.) should be controlled before entry into the study by appropriate medication which should be, if possible, continued unchanged during the entire study period.
研究者
相似试验
进行中（未招募）
不适用
Assessment of the early efficacy response rate of leflunomide according to the initial dosing regimen in the treatment of naive - DMARD early RA-patients. - LEADERPatients with a diagnosis of early active rhematoid arthritis in the previous 6 months, naive of previous treatment by DMARD and who need to be treated by DMARD.MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2007-000886-40-ITsanofi-aventis Groupe200
进行中（未招募）
不适用
Assessment of the early efficacy response rate of leflunomide according to the initial dosing regimen in the treatment of naïve-DMARD early RA-patients. - LEADERpatients with a diagnosis of early active rheumatoid arthritis in the previous 6 months, naïves of previous treatment by a DMARD and who need to be treated by a DMARDMedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2007-000886-40-PTsanofi-aventis groupe200
已完成
不适用
Study of the effectiveness of the response and interferon combination therapy for ribavirin monotherapy for chronic hepatitis CChronic hepatitis CJPRN-UMIN000017560Hokkaido University30
已完成
Unknown
A study to evaluate the dose-response efficacy of body fat reduction by continuous ingestion of test food. (SWE-2023-07-HCRINK)ot applicableJPRN-UMIN000051748Suntory Wellness Limited200
已完成
不适用
Comparison of the effect of DiphenCiprone alone and DiphenCiprone with intralesional injection of platelet-rich plasma in alopecia areataIRCT20200130046311N1Tehran University of Medical Sciences20